The Leading European Conference in HEOR Is Now Available On
Demand Through Year End
Lawrenceville, NJ, USA—November 23, 2020—ISPOR—The Professional Society for Health Economics
and Outcomes Research held its Virtual
ISPOR Europe 2020 conference, “Improving Health: Establishing Incentives
and Sharing Value,” on 16-19 November. ISPOR Europe is the leading European
conference for health economics and outcomes research (HEOR). On-demand
recordings of all conference sessions are available to registrants through 31
December 2020.
The first plenary
session, “’New
Deal’ for Healthcare Systems—Mission Inspirational, Impossible, or Inevitable?,” was held Monday, 16
November. The panel discussed the value of innovation in HEOR with moderator
Paola Testori Coggi, formerly with the European Commission and Italian
Medicines Agency, and panelists Natasha Azzopardi-Muscat, MD, PhD, World Health
Organization Europe; Nathalie Moll, European Federation of Pharmaceutical
Industries and Associations; Fabio Pammolli, Politecnico di Milano; and Jack
Scannell, PhD, JW Scannell Analytics Ltd and University of Edinburgh.
The second plenary
session, “Patient
and Public Involvement in Healthcare Decision Making: Are We Maximizing
Opportunities?,” was held Tuesday, 17 November. This session examined the urgent
need for a more holistic and meaningful approach to citizen involvement in
healthcare decision making. Speakers included moderator Bettina Ryll, MD, PhD,
Melanoma Patient Network Europe and panelists Nathalie Bere, MSc, European
Medicines Agency; Yann Le Cam, MBA, EURORDIS; and Axel Mühlbacher, PhD, MBA,
Hochschule Neubrandenburg.
The third plenary
session, “Much
Ado About Little: Dealing with Limited Randomized Controlled Trial (RCT)
Evidence for Early Health Technology Assessment (HTA) and Reimbursement
Decisions,” was held Wednesday, 18 November. This session focused on
the approval of innovative drugs with little or no RCT evidence. Speakers
included moderator Mark Sculpher, PhD, University of York and panelists Sylwia
Bujkiewicz, PhD, University of Leicester; Eva Susanne Dietrich, MD, Institute
for Evidence-Based Positioning in the Healthcare Sector and University of Bonn,
Pharmaceutical Institute; Stephen Palmer, PhD, University of York; and Uwe
Siebert, MD, MPH, MSc, ScD, University for Health Sciences, Medical Informatics
and Technology and Harvard Chan School of Public Health.
Three Spotlight Sessions
were held. “Scientific
Collaboration in the Face of a Pandemic,” featured moderator Ian Hudson, OBE, MBBS, MD with
the Bill and Melinda Gates Foundation and panelists Peter Marks, MD, PhD with
the US Food and Drug Administration; Pierre Meulien, PhD with the Innovative Medicines
Initiative; and Agnes Saint-Raymond, MD with the European Medicines Agency. “Is
Credible, Robust Real-World Evidence Just a Myth?” included moderator Anja
Schiel, PhD with the Norwegian Medicines Agency and panelists Nancy Dreyer,
MPH, PhD with IQVIA; Robert Golub, MD with JAMA; and Xavier Kurz, MD, PhD with
the European Medicines Agency. “Novel
Methods for Modeling Treatment Sequencing” featured moderator Mark
Sculpher, PhD with the University of York and panelists Maiwenn J Al, PhD with Erasmus
University Rotterdam; Huajie Jin, MBBS, MSc with King’s College London; and James
Robins, MD with the Harvard T.H. Chan School of Public Health.
ISPOR’s Women in HEOR initiative held a session, “Adapting
to the ‘New Normal,’“ that featured a panel of accomplished women in the field
discussing how HEOR professionals can manage their careers during the era of
COVID-19. The session featured the initiative’s co-leads, Olivia
Wu, PhD with the University of Glasgow who moderated and Julia F. Slejko,
PhD with the University of Maryland who hosted. Panelists included Blythe
Adamson, PhD, MPH with Flatiron Health; Nancy J. Devlin,
PhD with the University of Melbourne and ISPOR Past President; Ebere Onukwugha,
PhD with the University of Maryland and a member of the ISPOR Board of
Directors, and Louise Timlin, MSc with Eli Lilly and
Company.
ISPOR’s Value & Outcomes
Spotlight, the Society’s magazine for the HEOR community, published a
special supplement reporting on the conference—"Spotlight
on Virtual ISPOR Europe 2020.” Reporting on the conference included each of the plenary
sessions and a wide variety of topics, including the COVID-19
trial tracker, international
reference pricing, the meaning
and value of “cure”, SARS-CoV-2
contact tracing policies, histology
independent therapies, efficiencies
in HTA, COVID-19
and digital health, caregiver
burden in HEOR, HTA
during a pandemic, the SIR
model for resource allocation, HTA
for gene therapies, revising
guidelines with new technologies, multinational
HTA, the new
GRACE model,
and surrogate
endpoints in regulatory ad HTA. The entire special supplement can be found here.
The Society’s 2020 Outstanding
Regional Chapter Award honorees were also announced at the conference. The
large-category honoree is the ISPOR Mexico Chapter. The medium-category honoree
is the ISPOR Mongolia Chapter, and the small-category honoree is the ISPOR
Austria Chapter.
“Virtual ISPOR Europe 2020 is the Society’s first fully
virtual European conference,” stated ISPOR CEO and Executive Director Nancy S.
Berg. “While the COVID-19 pandemic necessitated a fully virtual event this year,
we were so pleased to be able to offer more than 90 hours of innovative and
topical educational programming to registrants from around the globe. ISPOR’s
virtual conferences have been extremely successful and well received. In fact,
when we are able to safely meet in person again, ISPOR plans to offer hybrid
conferences that offer both in-person and virtual attendance options for
registrants.”
On-demand recordings of all conference sessions are
available for registrants to view at their leisure through 30 December 2020. Registration will remain open through
that same time period. The ISPOR
Short Course Program is now also being offered
virtually with a wide variety of course topics. Short courses are posted here as they become
available.
ISPOR is recognized globally as the leading
professional society for health economics and outcomes research and its role in
improving healthcare decisions. Virtual ISPOR Europe 2020 drew healthcare
stakeholders with an interest in HEOR, including researchers and academicians,
assessors and regulators, payers and policymakers, the life sciences industry,
healthcare providers, and patient engagement organizations.
Additional information on the conference can be found at Conference
Information.
###
ABOUT ISPOR
ISPOR, the professional society for health economics
and outcomes research (HEOR), is an international, multistakeholder, nonprofit
dedicated to advancing HEOR excellence to improve decision making for health
globally. The Society is the leading source for scientific conferences,
peer-reviewed and MEDLINE®-indexed publications, good practices
guidance, education, collaboration, and tools/resources in the field.
Website | LinkedIn | Twitter (@ispororg) | YouTube | Facebook | Instagram